Fenofibrate Therapy in Carnitine Palmitoyl Transferase Type 2 Deficiency

Table 2

Changes in acylcarnitine levels (umol/L) with therapy.

Months	Lipid therapy	C16:0; (𝑅^#<0.65)	C18:0; (𝑅 0.02–0.10)	C18:1; (𝑅<0.02)	C18:1-OH; (𝑅^# n/a)	C2:0; (𝑅 3–23)	C3:0; (𝑅<0.66)	C total; (𝑅 21–70)	C free; (𝑅 13–56)
1	Nil	1.6	0.84	2.64		21	n/a	95	66
7	Fenofibrate 145 mg + Ezetimibe 10 mg	0.3	0.46	0.14		n/a	0.71	105	91
17	Fenofibrate 145 mg	1.3	1.34	0.72	0.02	13	0.71	86	68
30	Nil	1.8	2.6	0.8	0.80	20	0.80	104	76
33	Fenofibrate 96 mg	1.2	0.44	1.46	n/a	20	0.79	145	119

^#𝑅: provisional reference interval (umol/L).
C16:0: palmitoylcarnitine; C18:0: stearoylcarnitine; C18:1: oleoylcarnitine; C2:0: acetylcarnitine; C3:0: propionylcarnitine; C18:1-OH: hydroxyoleylcarnitine; C total: total carnitine; C free: free carnitine.